Targeted therapy and its availability in Serbia

Abstract

SUMMARYTargeted therapy has made a significant breakthrough for the treatment of different kind of severe diseases, mostly oncological and autoimmune ones. Biological or biotech products, as well as small synthetic molecules, like family of tyrosine kinase inhibitors, have already expressed their efficacy in several important indications. Their availability on the market and reimbursement possibility is of great importance, especially for the patients needed to be on lifelong therapies. Targeted therapy enhanced progression free and overall survival in many conditions, but also a number of these therapies produced important and severe side effects. Considering the fact that targeted therapy is on the global market relatively shortly, there is necessity for prolonged therapy monitoring: for further effectiveness assessment, for safety profile and long term health consequences establishment. Reimbursed targeted therapy proved its benefits that overweight risks, but still remains extremely high costs problem for its application. For an upper middle income country like Serbia, with significantly lower health care expenditures per capita than in other well developed countries, the availability of this expensive therapy is not yet gratifying.

Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria

“…In general, the access to modern onco-hematology therapies is limited that has been also reported by other studies from the region (26).…”

Malignant Lymphatic and Hematopoietic Neoplasms Mortality in Serbia, 1991–2010: A Joinpoint Regression Analysis

“…The last decades have several major improvements in the treatment of leukemias and lymphomas in Serbia, such as introduction of bone marrow transplantation (available in two hospitals), imatinib in Serbia was authorized by Medicines and Medical Devices Agency of Serbia in 2002, and rituximab in 1998, and the standard treatment for each MLHN disease in Serbia was approved according to the world standard recommendations [56] , [57] , [58] . In Serbia, which is one of the medium-developed countries on the basis of the gross domestic income, expenditures for health care per capita are much lower than in well-developed countries, and therefore the availability of treatment has not always been gratifying in the past.…”

Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report

“…Our findings are of great relevance for Serbia, where the value-based turnover of mAbs prescribed in oncology grew almost twenty times over only 9 years, from just over €1 million in 2004 to nearly €20 million in 2012. Therefore, the policymakers should take this into account in order not to cross the upper limits of affordability in our middle-income South-Eastern European economy (Jakovljevic, 2014; Kovacevic et al, 2014, 2015b).…”